Avadel Pharma (AVDL) Stock Forecast & Price Target
Avadel Pharma (AVDL) Analyst Ratings
Bulls say
Avadel Pharmaceuticals PLC demonstrates a positive outlook driven by its innovative product, LUMRYZ, which is anticipated to generate over $500 million in peak sales due to its once-nightly dosing convenience compared to other sodium oxybates. The company's management has maintained financial guidance, projecting a year-over-year sales increase to $240-$260 million by year-end 2025, with patient counts expected to rise by 40%. Furthermore, favorable trends in patient enrollments and the potential for expansion into new therapeutic indications suggest robust growth opportunities ahead.
Bears say
Avadel Pharmaceuticals faces a challenging outlook due to anticipated declines in LUMRYZ sales, with projected first-quarter figures indicating a muted performance influenced by seasonal dynamics and insurance re-authorizations. The company's value proposition in the narcolepsy treatment market may not meet sales expectations, further compounding concerns regarding its ability to compete effectively with larger competitor Jazz Pharmaceuticals. Additionally, the potential for underperformance in sales growth raises questions about the company's valuation and the market's perception of its financial prospects moving forward.
This aggregate rating is based on analysts' research of Avadel Pharma and is not a guaranteed prediction by Public.com or investment advice.
Avadel Pharma (AVDL) Analyst Forecast & Price Prediction
Start investing in Avadel Pharma (AVDL)
Order type
Buy in
Order amount
Est. shares
0 shares